Seeking Alpha

QualityStocks'  Instablog

QualityStocks
Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
QualityStocks
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • VentriPoint Diagnostics Ltd. (VPTDF) VMS™ Technology Notches Favorable Feedback Worldwide 0 comments
    Jun 21, 2013 1:36 PM | about stocks: VPTDF

    VentriPoint Diagnostics has designed a heart visualization system designed to benefit doctors, patients, and the overall healthcare industry by reducing time and costs of the procedure. The system uses a 2D echo to make a 3D model of the heart to evaluate right heart function and get the same information obtained from an MRI, but in a fraction of the time.

    As company CEO George Adams recently stated in an interview, the biggest beneficiary of the system is the patient. While cardiac MRIs can take anywhere between 30-90 minutes and take up to three months to get results, with VentriPoint's VMS™ system the procedure is done within 10 minutes producing immediate results. This time advantage is especially significant for children and adults who have a hard time lying still or are anxious within confined spaces, as is necessary with traditional MRI procedures.

    VentriPoint has already installed the system at multiple sites in the United States and overseas, and has received positive feedback across the board.

    "The VMS is non-invasive and repeatable as compared to MRI, and we are confident in the results using routine clinical scanning. At Evelina, all children undergoing MRI must have a general anesthetic. This is not required for the VMS and is a major improvement as we will not have to subject these children to the added complexity and risk of a general anesthetic." -John Simpson, MD, director of the Echocardiography Laboratory at Evelina Hospital in London, UK.

    As of now, the VMS™ is for investigational use only in the United States and has been approved for clinical use in Canada and Europe. VentriPoint in April received from the U.S. FDA a request for additional information as the agency completes the review of Pulmonary Arterial Hypertension (NYSE:PAH) 510(k). The company must now show the FDA that its technology works as well as MRI, as has already been demonstrated in other parts of the world.

    "The VentriPoint system combines the best of both worlds: the ease and availability of 2D echo and the intrinsic 3D information of the MRI acquired shapes of the right ventricle in the database. We anticipate a reduction of the need for (expensive) cardiac Magnetic Resonance Imaging (MRI) for the purpose of assessment of right ventricle volumes." -Willem Helbing MD, head of Pediatric Cardiology at Erasmus Sophia Children's Hospital in Rotterdam, Netherlands.

    For more information, visit ventripoint.com

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

    Stocks: VPTDF
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.